Satellos Bioscience Inc. (MSCLF)

Last Closing Price: --

Company Description

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-12.37M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -708.74%
Current Ratio (Most Recent Fiscal Quarter) --
Quick Ratio (Most Recent Fiscal Quarter) --
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $-0.07
Earnings per Share (Most Recent Fiscal Quarter) $-0.04
Earnings per Share (Most Recent Fiscal Year) $-0.21
Diluted Earnings per Share (Trailing 12 Months) $-0.19
Exchange --
Sector --
Industry --
Common Shares Outstanding 41.80M
Free Float --
Market Capitalization $7.94M
Average Volume (Last 20 Days) 3568.30
Beta (Past 60 Months) 2.04
Percentage Held By Insiders (Latest Annual Proxy Report) --
Percentage Held By Institutions (Latest 13F Reports) 0.00%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%